JLE

Hépato-Gastro & Oncologie Digestive

MENU

Benign liver tumors Volume 21, issue 5, Mai 2014

Figures


  • Figure 1

  • Figure 2

  • Figure 3

  • Figure 4

  • Figure 5

  • Figure 6

  • Figure 7

  • Figure 8

  • Figure 9

Tables

Authors
1 Hôpital Beaujon,
département d’anatomie pathologique,
110 avenue du général Leclerc,
92118 Clichy,
France
2 INSERM 1149,
Centre de recherche sur l’inflammation,
Université Paris Diderot,
Paris,
France
* Tirés à part

Benign hepatocellular tumors include 2 main entities, focal nodular hyperplasias (FNH) and hepatocellular adenomas (HCA). Both tumors, preferentially observed in young women without underlying chronic liver disease, display specific characteristics, in terms of pathophysiology, morphology and molecular features. Based on morphological and molecular characteristics, HCA are now recognized as a heterogeneous entity including 4 different subtypes (1) Telangiectatic/inflammatory, (2) Steatotic HNF1α inactivated, (3) β-catenin activated and (4) unclassifed. Importantly, pathomolecular classification has significant clinical impact outlining higher risk of complications, hemorrage in Telangiectatic/inflammatory subtype, and malignant transformation towards hepatocellular carcinoma in β-catenin activated. Regarding management, abstention remains the rule in the vast majority of FNH, while follow-up or surgical resection are recommended for HCA according to 3 criteria including gender, HCA subtype and size.